Drugmaker Moderna Inc. sent out its first batch of a experimental coronavirus vaccine to be tested in humans; eptinezumab, sold as Vyepti and developed by Lundbeck, was approved by the FDA as a migraine prevention therapy; a US appeals court upheld a Trump administration rule on abortion referrals.
Yesterday, drugmaker Moderna Inc. shipped the first batch of its developed coronavirus vaccine to US government researchers who will then test its efficacy for the first time in a human cohort trial, according to The Wall Street Journal. The vaccine was rapidly developed by the manufacturers in 3 months and will be tested on 20-25 healthy volunteers in April to determine whether 2 doses will be safe and generate an immune response to protect against infection. Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said that results will be available in July or August.
Eptinezumab, sold as Vyepti and developed by drugmaker Lundbeck, was approved by the FDA as a migraine prevention therapy, adding to the available class of biologic drugs that are laboratory-produced molecules engineered to serve as substitute disease-fighting antibodies. Reuters reports that the drug will be administered via intravenous infusion; it works to inhibit the calcitonin gene-related peptide, a known catalyst for migraine pain development.
The US 9th Circuit Court of Appeals ruled Monday to uphold a 2019 Trump administration rule that denies family planning grants to clinics that make referrals for abortion, according to the Los Angeles Times. The decision additionally overturned injunctions issued by different judges in 3 Western states, including California. The split 7-4 party line ruling was an en banc review, which means all of the district court judges have a chance to weigh in on a previous decision rendered by a 3-judge panel. Since taking office, President Trump has been actively replacing federal judges with those with Republican backgrounds.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
2 Commerce Drive
Cranbury, NJ 08512